ERCC1随机前瞻性生物标志物试验:在晚期非小细胞肺癌中比较铂类与非铂类治疗:ERCC1试验(ET)
这项III期随机试验以ERCC1(8F1抗体)状态分层,评估非铂方案对比铂类双药在ERCC1阳性晚期非小细胞肺癌的优效性及ERCC1阴性者的非劣效性。鳞癌患者中非铂方案总生存劣于铂类(中位OS 7.6 vs 10.7个月,HR 1.46,P=0.02),非鳞癌患者中两组无显著差异。结论:用市售ERCC1或XPF抗体选择化疗未带来额外生存获益。
要点
- 鳞癌患者中,紫杉醇+吉西他滨较顺铂+吉西他滨中位OS缩短(7.6 vs 10.7个月,HR 1.46,P=0.02)。
- 非鳞癌ERCC1阳性者,紫杉醇+培美曲塞与顺铂+培美曲塞中位OS无显著差异(8.0 vs 9.6个月,HR 1.11,95%CI 0.85-1.44)。
- ERCC1与XPF均无预后价值:非鳞癌中阳性 vs 阴性的OS HR分别为1.11(P=0.32)和1.08(P=0.55)。
核心结论
- 鳞癌患者接受铂类治疗较非铂化疗观察到更优结局;但使用市售ERCC1或XPF抗体选择化疗未带来额外生存获益。
研究设计与样本
- 采用标志物-治疗交互的III期设计,以ERCC1(8F1抗体)状态作为随机分层因素。
- 入组初治的IIIB和IV期非小细胞肺癌患者,共648例(鳞癌177例,非鳞癌471例)。
- 鳞癌患者随机接受顺铂+吉西他滨或紫杉醇+吉西他滨;非鳞癌患者接受顺铂+培美曲塞或紫杉醇+培美曲塞。
- 主要终点为总生存(OS),并评估XPF特异性抗体(克隆3F2)。
- ERCC1阳性患者的目标风险比(HR)≤0.78。
主要发现
- 非鳞癌和鳞癌患者的ERCC1阳性率分别为54.5%和76.7%,XPF阳性率分别为70.5%和68.5%。
- 鳞癌患者中,非铂方案较铂类中位OS缩短(7.6个月 vs 10.7个月;HR 1.46;P=0.02),2012年因OS劣效提前停止入组。
- ERCC1阳性非鳞癌患者中,紫杉醇+培美曲塞与顺铂+培美曲塞中位OS为8.0 vs 9.6个月(HR 1.11;95%CI 0.85-1.44)。
- ERCC1阴性非鳞癌患者中,紫杉醇+培美曲塞与顺铂+培美曲塞中位OS为10.3 vs 11.6个月(HR 0.99;95%CI 0.73-1.33;交互P=0.64)。
- XPF阳性患者OS HR为1.09(95%CI 0.83-1.44),XPF阴性患者为1.39(95%CI 0.90-2.15;交互P=0.35)。
关键数值与推荐
- ERCC1阳性非鳞癌:紫杉醇+培美曲塞 vs 顺铂+培美曲塞中位OS 8.0 vs 9.6个月,HR 1.11(95%CI 0.85-1.44)。
- ERCC1阴性非鳞癌:紫杉醇+培美曲塞 vs 顺铂+培美曲塞中位OS 10.3 vs 11.6个月,HR 0.99(95%CI 0.73-1.33)。
- 鳞癌:紫杉醇+吉西他滨 vs 顺铂+吉西他滨中位OS 7.6 vs 10.7个月,HR 1.46(P=0.02)。
- XPF阳性:OS HR 1.09(95%CI 0.83-1.44);XPF阴性:OS HR 1.39(95%CI 0.90-2.15)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 鳞癌患者入组于2012年因非铂方案OS劣于铂类而提前停止。
- 非鳞癌患者入组于2013年停止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Retrospective studies indicate that expression of excision repair cross complementing group 1 (ERCC1) protein is associated with platinum resistance and survival in non-small-cell lung cancer (NSCLC). We conducted the first randomized trial, to our knowledge, to evaluate ERCC1 prospectively and to assess the superiority of nonplatinum therapy over platinum doublet therapy for ERCC1-positive NSCLC as well as noninferiority for ERCC1-negative NSCLC. Patients and Methods This trial had a marker-by-treatment interaction phase III design, with ERCC1 (8F1 antibody) status as a randomization stratification factor. Chemonaïve patients with NSCLC (stage IIIB and IV) were eligible. Patients with squamous histology were randomly assigned to cisplatin and gemcitabine or paclitaxel and gemcitabine; nonsquamous patients received cisplatin and pemetrexed or paclitaxel and pemetrexed. Primary end point was overall survival (OS). We also evaluated an antibody specific for XPF (clone 3F2). The target hazard ratio (HR) for patients with ERCC1-positive NSCLC was ≤ 0.78. Results Of patients, 648 were recruited (177 squamous, 471 nonsquamous). ERCC1-positive rates were 54.5% and 76.7% in nonsquamous and squamous patients, respectively, and the corresponding XPF-positive rates were 70.5% and 68.5%. Accrual stopped early in 2012 for squamous patients because OS for nonplatinum therapy was inferior to platinum therapy (median OS, 7.6 months [paclitaxel and gemcitabine] v 10.7 months [cisplatin and gemcitabine]; HR, 1.46; P = .02). Accrual for nonsquamous patients halted in 2013. Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months for ERCC1-positive patients (HR, 1.11; 95% CI, 0.85 to 1.44), and 10.3 (paclitaxel and pemetrexed) versus 11.6 (cisplatin and pemetrexed) months for ERCC1-negative patients (HR, 0.99; 95% CI, 0.73 to 1.33; interaction P = .64). OS HR was 1.09 (95% CI, 0.83 to 1.44) for XPF-positive patients, and 1.39 (95% CI, 0.90 to 2.15) for XPF-negative patients (interaction P = .35). Neither ERCC1 nor XPF were prognostic: among nonsquamous patients, OS HRs for positive versus negative were ERCC1, 1.11 ( P = .32), and XPF, 1.08 ( P = .55). Conclusion Superior outcomes were observed for patients with squamous histology who received platinum therapy compared with nonplatinum chemotherapy; however, selecting chemotherapy by using commercially available ERCC1 or XPF antibodies did not confer any extra survival benefit.
引用
- Lee SM, Falzon M, Blackhall F, et al. Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). J Clin Oncol. 2016. PMID: 27893326. doi:10.1200/JCO.2016.68.1841
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。